



## Pharmacogenomics and Hypertension: Problems and Prospects

Guest Editors:

**Prof. Dr. Brian L. Rayner**

Division of Nephrology and  
Hypertension, University of Cape  
Town, Cape Town, South Africa

**Prof. Dr. Collet Dandara**

Platform for Pharmacogenomics  
Research and Translation  
(PREMED), South African Medical  
Research Council & Division of  
Human Genetics, Faculty of  
Health Sciences, University of  
Cape Town, Cape Town, South  
Africa

Deadline for manuscript  
submissions:

**25 July 2025**

### Message from the Guest Editors

Arterial hypertension has a strong underlying hereditary and environmental basis. Treatment has remained empiric, control rates are suboptimal, and there is minimal translation of genetics from the bench to the clinic. Although rare monogenic forms of hypertension with a distinct phenotype were initially well documented and provided specific treatments, the overall genetic risk for hypertension was considered to be polygenetic in origin. The initial GWAS studies could only explain 2% of the overall risk, which led to a degree of nihilism in relation to the pharmacogenetics of hypertension.

The aim of this Special Issue is to review and publish cutting-edge research on new developments in the understanding of the genetics of arterial hypertension, the translation of genetic research to the clinic, and future directions for pharmacogenomics. We are soliciting original articles related to understanding the genetic architecture of hypertension, genetic risk scoring, Mendelian randomization, epigenetics, the pharmacokinetics and pharmacodynamics of antihypertensive drugs, translational research, and state-of-the-art manuscripts on the status of pharmacogenomics and future directions.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory  
Medicine and Pathobiology,  
Department of Surgery,  
University of Toronto, 6 Queens  
Pk Crescent W,F, Toronto, ON  
M5S 3H2, Canada

## Message from the Editor-in-Chief

*Journal of Personalized Medicine* (*JPM*; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [PubMed](#), [PMC](#), [Embase](#), and [other databases](#).

**Journal Rank:** CiteScore - Q1 (Medicine (miscellaneous))

## Contact Us

---

*Journal of Personalized Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/jpm](http://mdpi.com/journal/jpm)  
[jpm@mdpi.com](mailto:jpm@mdpi.com)  
[X@JPM\\_MDPI](https://twitter.com/JPM_MDPI)